Jo-1 Ab; PL-7 Ab; PL-12 Ab; EJ Ab; OJ Ab; SRP Ab; Mi-2 Alpha Ab; Mi-2 Alpha Ab; Mi-2 Beta Ab; MDA-5 Ab; TIF-1y Ab; NXP-2 Ab
Myositis-specific autoantibodies (MSAs) are highly selective, usually exclusive and are associated with particular clinical phenotypes within the myositis spectrum. Myositis-specific autoantibodies to cytoplasmic enzymes that catalyze the binding of specific amino acids to their cognate tRNA define the anti-synthetase syndrome characterized by myositis and lung inflammation, and include autoantibodies to Jo-1 (antihistidyl-tRNA synthetase), PL-7 (threonyl), PL-12 (alanyl), EJ (glycyl), and OJ (isoleucyl). A further subset of myositis patients is characterized by the presence of autoantibodies directed against the signal recognition particle (SRP). Autoantibodies to Mi-2 (Mi-2/nucleosome remodelling and deacetylase (NuRD) complex) are detected in patients with hallmark dermatomyositis features. Autoantibody to a cytoplasmic 140-kDa protein, melanoma-differentiation associated gene 5 (MDA5), also known as anti-CADM140, identified patients with clinically amyopathic dermatomyositis (CADM) and rapidly progressive lung disease. Autoantibodies to transcriptional intermediary factor 1-gamma (TIF-1 y), a p155/140 nuclear protein involved in cellular differentiation, have been reported in adult and juvenile dermatomyositis; in adults, it is associated with malignancy. Autoantibodies to nuclear matrix protein NXP-2, another 140-kDa protein, is found in juvenile dermatomyositis (JDM). Anti-TIF-1 y and anti-NXP-2, two novel serological subsets in JDM, occur collectively in >40% of children and appear to identify those with more severe disease.
1.0 mL Serum from a SST Gold Top Tube
7 Days Ambient
14 days Refrigerator
28 days Frozen
Separate serum from cells within 4 hours of collection
Transfer to a transport tube and ship by overnight courier
0.3 mL Serum
| Jo-1 Ab | <11 SI |
| PL-7 Ab | <11 SI |
| PL-12 Ab | <11 SI |
| EJ Ab | <11 SI |
| OJ Ab | <11 SI |
| SRP Ab | <11 SI |
| Mi-2 Alpha Ab | <11 SI |
| Mi-2 Beta Ab | <11 SI |
| MDA-5 Ab | <11 SI |
| TIF-1Gamma Ab | <11 SI |
| NXP-2 Ab | <11 SI |
Myositis-specific autoantibodies (MSAs) are highly selective, usually exclusive and are associated with particular clinical phenotypes within the myositis spectrum. Myositis-specific autoantibodies to cytoplasmic enzymes that catalyze the binding of specific amino acids to their cognate tRNA define the anti-synthetase syndrome characterized by myositis and lung inflammation, and include autoantibodies to Jo-1 (antihistidyl-tRNA synthetase), PL-7 (threonyl), PL-12 (alanyl), EJ (glycyl), and OJ (isoleucyl). A further subset of myositis patients is characterized by the presence of autoantibodies directed against the signal recognition particle (SRP). Autoantibodies to Mi-2 (Mi-2/nucleosome remodelling and deacetylase (NuRD) complex) are detected in patients with hallmark dermatomyositis features. Autoantibody to a cytoplasmic 140-kDa protein, melanoma-differentiation associated gene 5 (MDA5), also known as anti-CADM140, identified patients with clinically amyopathic dermatomyositis (CADM) and rapidly progressive lung disease. Autoantibodies to transcriptional intermediary factor 1-gamma (TIF-1 y), a p155/140 nuclear protein involved in cellular differentiation, have been reported in adult and juvenile dermatomyositis; in adults, it is associated with malignancy. Autoantibodies to nuclear matrix protein NXP-2, another 140-kDa protein, is found in juvenile dermatomyositis (JDM). Anti-TIF-1 y and anti-NXP-2, two novel serological subsets in JDM, occur collectively in >40% of children and appear to identify those with more severe disease.
5 to 6 days
00913333
84182 (x6), 86235 (x5)